Treats Attention Deficit Hyperactivity Disorder (ADHD). ANDA 213428, held by Yichang Humanwell. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 213428 (Guanfacine Hydrochloride), held by Yichang Humanwell, was first approved by FDA on Nov 25, 2020, with 0 approved supplements and 0 published complete response letters.
Guanfacine Extended-Release Tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 2020 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 3MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 4MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters